BPC-157 Research, Specifications & Scientific Information

Introduction

BPC-157 occupies an unusual position in peptide research: a very large preclinical literature, an almost empty human one, and no identified molecular target. It is a synthetic peptide of fifteen residues, and the literature describes its sequence as a partial sequence of a protein fraction isolated from human gastric juice — "body protection compound" — a parent protein that has never itself been isolated and sequenced. Since the early 1990s the peptide has been examined in rodent models across a remarkable breadth of tissues, and a large share of that work comes from one group in Zagreb. What has not accumulated alongside it is human evidence. A systematic review published in 2025 screened 544 articles and found that 35 of the 36 it included were preclinical ^[6].

This page is a reference record. It sets out what has been published about the peptide's structure, the pathways reported for it, and the shape and the limits of its evidence base, with every source resolved against PubMed, Crossref or ClinicalTrials.gov at the time the page was built. It describes research. It does not describe use in people or animals, and it contains no guidance of any kind on handling the material.

What Is BPC-157?

BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV. It is not an approved medicine in the United States and has not been approved by the U.S. Food and Drug Administration for any indication.

The name is an abbreviation of "body protection compound", the term applied to a protein fraction of human gastric juice from which the fifteen-residue sequence was said to derive. That derivation is worth stating carefully, because it is routinely reported as though the peptide were a characterised cleavage product of a known gene: the complete parent protein has not been isolated and sequenced, and BPC-157 is best described as a synthetic peptide of defined sequence whose stated origin is a gastric juice fraction.

Several development codes appear in the literature for the same molecule. Pliva carried it as PL 14736 and PLD-116 while developing it as an agent for inflammatory bowel disease ^[1]; a later registered phase 1 protocol carried it as PCO-02, with the active ingredient named Bepecin ^[11]. Public registers hold it under CAS registry number 137525-51-0, PubChem CID 9941957 and UNII 8ED8NXK95P.

A 2026 review of the compound from a drug-development perspective summarised the position bluntly: after more than three decades of preclinical research, there is no approved formulation, no validated administration regimen and no completed phase 2 clinical trial ^[8].

BPC-157 Specifications

The fifteen-residue sequence GEPPPGKPADDAGLV is the sequence recorded for BPC-157 in PubChem under CID 9941957 and in the FDA/NCATS Global Substance Registration System under UNII 8ED8NXK95P, both of which also carry CAS registry number 137525-51-0. All fifteen residues are standard L-amino acids written in single-letter code; the register records no acylation, no cyclisation, no amidation and no non-standard residue, so unlike most modified peptides in this catalog the single-letter string here is the complete covalent structure. Five of the fifteen positions are proline, which is the structural reason usually given in the literature for the peptide's unusual resistance to degradation in gastric juice. The molecular formula and mass shown are the values PubChem calculates for the free acid and match the figures carried in the supplier catalog. One point of nomenclature is worth stating plainly because it is a frequent source of confusion: the parent protein, 'body protection compound', has never been isolated and sequenced as a complete protein, and the literature describes BPC-157 as a partial sequence of a gastric juice fraction rather than as a cleavage product of a characterised gene product. Any figure on this page is a reference value; the certificate of analysis supplied with a laboratory order is the record for a given lot.

Values that a public register does not carry are shown as not publicly characterised rather than estimated. Identifiers are reference values; the certificate of analysis supplied with a laboratory order is the record for a given lot.

How Does BPC-157 Work?

The honest answer is that nobody knows, and that the published mechanism is a list of downstream observations rather than an account of a binding event.

No receptor for BPC-157 has been identified. There is no reported binding affinity at any characterised target, no receptor family, and no agonist or antagonist classification — which is why those rows in the specification table above are blank rather than filled in. Every mechanistic claim in the literature is of the form "after exposure to the peptide, this pathway was more active", and the pathways most consistently named are vascular endothelial growth factor receptor 2 signalling, nitric oxide synthesis, focal adhesion signalling in fibroblasts, and growth hormone receptor expression ^{[5, 3, 4]}.

A second unresolved problem sits underneath all of it. A formal preclinical absorption, distribution, metabolism and excretion study in two species reports a plasma half-life under 30 minutes with approximately linear kinetics and intramuscular bioavailability between 14% and 51% depending on species. The biological effects described in rodent models persist for hours to days. That disconnect between residence time and duration of effect has not been explained, and the review that sets it out treats it as a central obstacle to development rather than a curiosity ^[8].

BPC-157 Mechanism of Action

In vitro research

The cell-culture literature is where the mechanistic claims originate, and it is more specific than the animal literature that surrounds it.

Fibroblast behaviour and focal adhesion signalling. In tendon explants and isolated tendon fibroblasts from rat Achilles tendon, exposure to the peptide accelerated outgrowth from the explant and increased migration in a transwell assay in proportion to concentration, while proliferation measured by MTT assay was unchanged. Cell survival under hydrogen peroxide stress increased. Phosphorylation of focal adhesion kinase and of paxillin rose with concentration while total protein amounts were unaltered, and F-actin formation was induced ^[3]. The authors' own summary is that the effect is on migration and survival rather than on proliferation — a distinction that is often lost when this work is cited second-hand.

Growth hormone receptor expression. A cDNA microarray of rat tendon fibroblasts identified the growth hormone receptor as one of the most abundantly up-regulated genes after exposure. The up-regulation was confirmed at mRNA and protein level by RT-PCR and Western blot, and adding growth hormone to exposed fibroblasts increased proliferation and activated Janus kinase 2 ^[4]. The mechanism proposed is therefore indirect: a change in sensitivity to a hormone, not an action of the peptide itself.

VEGFR2 expression and internalisation. In human vascular endothelial cells, exposure increased mRNA and protein expression of vascular endothelial growth factor receptor 2 but not of VEGF-A, and promoted receptor internalisation. Internalisation, the activation of VEGFR2–Akt–eNOS signalling, and the increase in endothelial tube formation were all blocked by dynasore, an inhibitor of endocytosis ^[5]. The dependence on endocytosis is the most mechanistically specific finding in the BPC-157 literature.

These are observations in cultured cells. They describe what cells did in a dish and establish nothing about animals or about people.

What Is BPC-157 Being Researched For?

Animal research

Nearly all published research on BPC-157 is research in rodents, and the range of models is unusually wide for a single compound. The models that recur are:

• Tendon and tendon-to-bone models. Sharp transection of the rat Achilles tendon from the calcaneus, assessed functionally, biomechanically and histologically ^{[1, 10]}.
• Transected striated tissue. Transection of the rat quadriceps, assessed by the same battery ^[2].
• Vascular and ischaemic models. Rat hind-limb ischaemia with blood-flow measurement by laser Doppler scanning, and the chick chorioallantoic membrane assay ^[5].
• Interaction with corticosteroids. Co-administration with 6α-methylprednisolone in the tendon-to-bone model, which the authors designed to test whether the peptide offsets corticosteroid aggravation ^[1].

The breadth is itself a feature of the evidence base worth noticing. A compound reported as active in tendon, striated tissue, vasculature, gut, eye and nervous tissue in the same programme either acts on something very general or is being assessed with methods that are not very specific, and the published literature does not settle which. Findings described in this section were observed in animals, and nothing in them establishes anything about humans.

Human Research on BPC-157

Human clinical research

Results from pharmaceutical clinical trials describe the investigational material and populations used in those studies and should not be interpreted as establishing the effects of research-grade materials offered for laboratory use.

There is no published, controlled human trial of BPC-157. That sentence is the most important one on this page, and the sections below exist to make it precise rather than to soften it.

What the systematic reviews found

A 2025 systematic review in the orthopaedic sports medicine literature searched PubMed, Cochrane and Embase from database inception to 3 June 2024, screened 544 articles in three phases by two reviewers, and included 36 studies: 35 preclinical and one clinical. The single clinical study was retrospective, and the review records that of 12 patients given an intra-articular administration for unspecified chronic knee pain, 7 reported relief lasting more than six months. The review states explicitly that no clinical safety data were found, and classifies the body of evidence it reviewed as level IV and level V ^[6].

A separate 2025 narrative review reached the same place by a different route: it identified three human pilot studies in total — intra-articular administration for knee pain, interstitial cystitis, and an intravenous safety and pharmacokinetic study — reported that no adverse effects were recorded in them, and concluded that rigorous large-scale trials are lacking and that the compound should be considered investigational ^[7].

Limitations. Both are reviews, not trials. A retrospective series of 12 people with no control group and an unspecified condition supports no inference about effect. The absence of reported adverse effects in three small pilots is not a safety finding; it is an absence of data.

The registered trials

Three human trials are registered on ClinicalTrials.gov.

Phase 1, healthy volunteers (PCO-02). A phase 1 pilot in healthy volunteers to assess safety and pharmacokinetics of an oral tablet formulation, sponsored by PharmaCotherapia, with a planned enrolment of 42 and a start date of October 2015. The registry record carries no posted results and its overall status is listed as unknown ^[11].

Phase 2, acute hamstring strain. A randomised, double-blind, placebo-controlled phase 2 trial with a planned enrolment of 120, sponsored by Hudson Biotech, which began recruiting in February 2026. Co-primary endpoints are time to return to unrestricted sport and change in magnetic-resonance-assessed lesion volume at day 14 ^[12].

Phase 1, rotator cuff repair. A randomised pilot with a planned enrolment of 30 at the University of Arkansas, estimated to start in January 2027 and not yet recruiting ^[13].

Limitations. One of the three has been registered for over a decade without reporting; the other two have not begun to produce data. A registered protocol is a statement of intent, not a result, and nothing in this subsection describes an outcome of any kind.

Preclinical Research on BPC-157

Animal research

Achilles tendon-to-bone in rats. After the rat Achilles tendon was sharply transected from the calcaneal bone, animals received the peptide at 10 µg, 10 ng or 10 pg per kilogram of body weight, 6α-methylprednisolone at 1 mg per kilogram, or 0.9% saline, alone or in combination, intraperitoneally once daily, beginning 30 minutes after surgery. Assessment at days 1, 4, 7, 10, 14 and 21 reported increased Achilles functional index values, significant increases in load to failure, stiffness and Young's elasticity modulus, better organisation of collagen fibres, more type I collagen and advanced vascular appearance. Methylprednisolone consistently worsened the same measures, and the peptide substantially reduced that worsening ^[1].

Transected quadriceps in rats. The same group applied a comparable design to complete transection of the rat quadriceps ^[2].

Hind-limb ischaemia in rats. Blood-flow restoration in the ischaemic rat hind limb was accelerated as measured by laser Doppler scanning, with histology of the limb tissue showing an increased number of vessels and increased vascular expression of VEGFR2 ^[5].

A comparison in the same model. A 2026 study assessed BPC-157 and TB-500 in the rat Achilles tendon model histopathologically and biomechanically, which is the only published head-to-head rodent comparison of the two compounds most often discussed together ^[10].

Three cautions apply to all of it. The models are acute surgical transections in young healthy rodents, which is not the situation the compound is popularly discussed in. The reported effects span an extraordinary range of administered amounts — picograms to micrograms per kilogram in the same experiment — which is unusual and is not accompanied by a concentration–response model that would explain it. And the concentration of authorship matters: the tendon and striated-tissue work cited here comes from one group at the University of Zagreb School of Medicine, and independent replication of the central findings is thin.

Findings described in this section were observed in animals, and nothing in them establishes anything about humans.

Other Areas of BPC-157 Research

In vitro research

Human arterial tissue, ex vivo. Residual internal mammary artery segments from twelve elective coronary artery bypass graft operations were dissected into endothelium-intact and endothelium-denuded rings, contracted with phenylephrine, and exposed to cumulative concentrations of BPC-157 from 0.01 to 1 mg/mL. Relaxation increased with concentration in both groups and was significantly greater in endothelium-intact rings. Pre-incubation with the nitric oxide synthase inhibitor L-NAME attenuated the relaxation and largely abolished the advantage of endothelial integrity, and the concentration–response curves converged at higher concentrations ^[9].

This is the closest thing in the literature to a measurement made in human tissue, and it is worth being exact about what it is: isolated artery rings in an organ bath, twelve donors, an acute pharmacological readout. The authors themselves describe it as early mechanistic evidence and state that further molecular and in vivo work is required before clinical relevance can be assessed ^[9].

Biopharmaceutics. The 2026 development review characterises the peptide as unusually stable in gastric juice and as showing activity by oral, parenteral and topical routes in preclinical models, while lacking biopharmaceutics classification data, permeability characterisation and formal excipient compatibility studies ^[8]. These are not efficacy questions; they are the prerequisites for making a medicine out of a molecule, and they have not been met.

Current Research Status

Status as of September 22, 2026. This block is rendered from maintained fields, not from prose, so it cannot go stale in one place and stay current in another.

BPC-157 vs Related Compounds

The compounds BPC-157 is usually set beside share a shelf, not a pathway. The distinctions below are compositional and pharmacological, and no comparison of effect is made between them.

Origin

BPC-157 — a fifteen-residue synthetic peptide whose sequence is described as part of a human gastric juice fraction. TB-500 — the acetylated seven-residue fragment corresponding to residues 17 to 23 of thymosin β4, a 43-residue intracellular protein. GHK-Cu — a three-residue peptide in complex with a copper(II) ion. KPV — the three C-terminal residues of α-melanocyte-stimulating hormone.

Identified target

BPC-157 — none. TB-500 and thymosin β4 — actin, through the β-thymosin/WH2 actin-binding motif. GHK-Cu — copper coordination rather than a receptor. KPV — derived from a melanocortin ligand, with activity reported at intracellular inflammatory signalling rather than at a melanocortin receptor.

Evidence shape

BPC-157 — a broad rodent literature and no published controlled human trial. Thymosin β4 — preclinical work plus several completed human trials of the full-length protein in ophthalmic and dermatological indications, none of them of the seven-residue fragment. GHK-Cu — chemistry and cell culture, with no indexed randomised clinical trial. KPV — rodent colitis models, with no registered human trial.

Regulatory position

None of the four is an approved medicine in the United States. Approval is specific to a compound and an indication and does not extend across a structural class or a marketing category.

Chemical & Molecular Characteristics

BPC-157 is a linear peptide of fifteen standard L-amino acids: GEPPPGKPADDAGLV.

Unusually for the peptides in this library, the single-letter string is the complete covalent structure. PubChem CID 9941957 and the FDA/NCATS Global Substance Registration System record under UNII 8ED8NXK95P both describe the free acid with no acylation, no C-terminal amidation, no cyclisation and no non-standard residue, and both carry CAS registry number 137525-51-0. The molecular formula C62H98N16O22 and the monoisotopic-derived average mass of 1419.5 g/mol are PubChem's calculated values for that structure, and they agree with the figures carried in the supplier catalog.

Three structural points are worth separating from the pharmacology.

The proline content is the structural story. Five of fifteen positions are proline, three of them consecutive. Proline-rich sequences resist proteolysis by most endopeptidases, and this is the structural feature usually cited to explain the peptide's reported stability in gastric juice ^[8]. Stability in an acidic protease-rich environment is a chemical property, and it is a separate question from whether an intact peptide crosses an epithelium.

Short plasma residence is well characterised; human kinetics are not. The preclinical half-life figure of under 30 minutes is consistent across species. The human literature contains a two-subject pilot figure and nothing else ^[8].

Nomenclature is not identity. "BPC" is a name for a gastric juice fraction, not for a sequenced protein, and "BPC-157" denotes a defined fifteen-residue synthetic peptide. Material sold under the name "BPC-157 arginate" or similar salt designations differs from the free acid described above in counter-ion and therefore in mass; the certificate of analysis for a given lot is the record of what a given lot is.

Analytical Specifications

Analytical figures are lot-specific. Fields the catalog does not carry for the current lot are omitted rather than filled with a typical value. The certificate of analysis and the safety data sheet for the exact lot supplied are provided with a laboratory order; no purity figure on this page is a substitute for that document.

Frequently Asked Questions

Scientific References

1. Krivic A, Anic T, Seiwerth S, et al.. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation Journal of orthopaedic research : official publication of the Orthopaedic Research Society; 2006. PMID 16583442 doi:10.1002/jor.20096
2. Staresinic M, Petrovic I, Novinscak T, et al.. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157 Journal of orthopaedic research : official publication of the Orthopaedic Research Society; 2006. PMID 16609979 doi:10.1002/jor.20089
3. Chang CH, Tsai WC, Lin MS, et al.. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration Journal of applied physiology (Bethesda, Md. : 1985); 2011. PMID 21030672 doi:10.1152/japplphysiol.00945.2010
4. Chang CH, Tsai WC, Hsu YH, et al.. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts Molecules (Basel, Switzerland); 2014. PMID 25415472 doi:10.3390/molecules191119066
5. Hsieh MJ, Liu HT, Wang CN, et al.. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation Journal of molecular medicine (Berlin, Germany); 2017. PMID 27847966 doi:10.1007/s00109-016-1488-y
6. Vasireddi N, Hahamyan H, Salata MJ, et al.. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review HSS journal : the musculoskeletal journal of Hospital for Special Surgery; 2025. PMID 40756949 doi:10.1177/15563316251355551
7. McGuire FP, Martinez R, Lenz A, et al.. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing Current reviews in musculoskeletal medicine; 2025. PMID 40789979 doi:10.1007/s12178-025-09990-7
8. Mateescu DM, Gavrilescu DM, Constantinescu FE, et al.. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Pharmaceutics; 2026. PMID 42198317 doi:10.3390/pharmaceutics18050625
9. Yildirim AK, Dastan AO, Demeli Ertus M, et al.. Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery Journal of clinical medicine; 2026. PMID 42123221 doi:10.3390/jcm15093488
10. Biçer O, Adanir O, Güleryüz Y, et al.. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study Joint diseases and related surgery; 2026. PMID 42542926 doi:10.52312/jdrs.2026.2951
11. PCO-02 - Safety and Pharmacokinetics Trial 2015. NCT02637284
12. BPC 157 for Acute Hamstring Muscle Strain Repair 2026. NCT07437547
13. Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery 2027. NCT07803250

Every identifier above is resolved against PubMed, Crossref or ClinicalTrials.gov at build time, and the title returned by the register is compared with the title stored here. A page does not publish if a reference fails to resolve.

Research-Use Information

For in vitro research use only. This material is a laboratory reagent. It is not a drug, food, dietary supplement, or cosmetic and is not for human or veterinary use, including ingestion, injection, or any other administration. No information on this page describes or implies any effect in humans or animals. Sold only to researchers under our Terms of Sale.

Related laboratory reagent: BPC-157 specifications and lot documentation